Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Department of Biochemistry and Molecular Biology, School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Biomater Sci. 2023 May 2;11(9):3016-3033. doi: 10.1039/d2bm02169b.
CRISPR, as an emerging gene-editing technology, has been widely used in multidisciplinary fields, including genetic diseases and some cancers. However, it remains a challenge to efficiently deliver CRISPR for safe and efficient genome editing. Currently, biomimetic materials have become an attractive delivery strategy for CRISPR-mediated genome editing due to their low immunogenicity and application safety. The biomimetic materials delivery is involved in the improvement of cellular uptake of nanoparticle vectors, and the gene editing efficiency. In this review, we summarize the current delivery strategies of CRISPR/Cas systems based on biogenic materials such as viruses, bacteria, cells, bioactive substances, ., focusing on the potential applications in disease research and therapy. Finally, the prospects and limitations of CRISPR-based systems in therapeutics are discussed.
CRISPR 作为一种新兴的基因编辑技术，已广泛应用于多个学科领域，包括遗传疾病和一些癌症。然而，高效地将 CRISPR 递送至靶细胞用于安全有效的基因组编辑仍然是一个挑战。目前，仿生材料由于其低免疫原性和应用安全性，已成为 CRISPR 介导的基因组编辑的一种有吸引力的递送策略。仿生材料的递送涉及提高纳米载体的细胞摄取效率和基因编辑效率。在本文中，我们总结了基于病毒、细菌、细胞、生物活性物质等生物源材料的 CRISPR/Cas 系统的现有递送策略，重点介绍了它们在疾病研究和治疗中的潜在应用。最后，讨论了基于 CRISPR 的系统在治疗中的前景和局限性。
